Arkolith/Insider Trading/SNDX/Form 4

Metzger Michael A

Chief Executive Officer, DirectorSyndax Pharmaceuticals Inc (SNDX) · full profile →Form 4 · filed Jul 9, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$785K
Net Open-Market Flow
-$785K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 8, 2026Option exercise(M)32K$6.38$207K517K
Jul 8, 2026Sell(S)32K$24.24$785K485K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 8, 2026Option exercise(M)32K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-299803) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML